EU regulator backs GSK’s rubella virus vaccine for use in adults aged 50-59 years
The European Union’s health regulator has recommended expanding the use of GSK’s respiratory syncytial virus (RSV) vaccine to adults aged 50-59 years. The vaccine, called Arexvy, was approved by the US Food and Drug Administration in June.
ПОПУЛЯРНЫЕ ПОСТЫ
Putin may discuss Ukraine peace deal with Trump
Ноябрь 22, 2024
Spain’s vice-president Ribera blames floods on climate change
Ноябрь 22, 2024
Storm lashes northwestern US, killing two people
Ноябрь 22, 2024
Iceland volcano erupts for tenth time in three years
Ноябрь 22, 2024
ПОДПИСЫВАЙТЕСЬ НА НАС
ПРЯМАЯ ТРАНСЛЯЦИЯ